BioMimetic Therapeutics, Inc. (BMTI)

[surf1944]

BioMimetic Therapeutics Inc. (BMTI)
Sector Healthcare
Industry Medical Instruments & Supplies
Market Cap $101.87M
Beta 0.90

BMTI stock chart

Key Metrics
Long Term Debt/Equity Ratio 0.00
5-Year Projected Earnings Per Share Growth Rate 35.00%
Short Interest 1.65%

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. The company's orthopedic products include Augment Bone Graft for open fracture and fusion treatment; and Augment Injectable Bone Graft for open or closed fracture treatment and minimally invasive fracture/fusion treatment.

Its products also comprise Augment Rotator Cuff Graft for rotator cuff tendon to bone repair; Augment OCD for cartilage and bone repair; TBD for the treatment of injuries due to tendon overuse; and Augment Bone Graft for spine fusion. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee.

http://seekingalpha.com/article/824171-5-low-debt-healthcare-stocks-positioned-for-growth?source=yahoo